<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02324309</url>
  </required_header>
  <id_info>
    <org_study_id>3-151</org_study_id>
    <nct_id>NCT02324309</nct_id>
  </id_info>
  <brief_title>BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance</brief_title>
  <official_title>A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin® R U-500 and Humalog® Mix75/25™ in Subjects With Type 2 DM Who Are Treated With ≥ 150 Units of Insulin Per Day</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biodel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biodel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to compare meal time glucose control associated with BIOD-531, a
      rapidly absorbed concentrated insulin to that associated with Humalog Mix 75/25 and Humulin R
      U-500 in patients with diabetes and severe insulin resistance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-breakfast glucose exposure (AUC)</measure>
    <time_frame>0-330 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Speed of insulin absorption (Times to 50%, 90%, maximal insulin concentrations)</measure>
    <time_frame>0-330 and 660-1020 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin exposure (AUC)</measure>
    <time_frame>0-1440 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal insulin concentration</measure>
    <time_frame>0-330 and 660-1020 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-lunch and post-dinner glucose exposures (AUC)</measure>
    <time_frame>330-660 and 660-1020 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection site toleration (VAS and severity scales)</measure>
    <time_frame>30 and 690 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>BIOD-531 pre-meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog Mix 75/25 pre-meal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humulin R U-500 pre-meal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIOD-531 post-meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injections of 1.2 U/kg 20 minutes after the start of a standardized breakfast and 0.8 U/kg 20 minutes after the start of a standardized dinner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIOD-531</intervention_name>
    <arm_group_label>BIOD-531 pre-meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog Mix 75/25</intervention_name>
    <arm_group_label>Humalog Mix 75/25 pre-meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humulin R U-500</intervention_name>
    <arm_group_label>Humulin R U-500 pre-meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIOD-531</intervention_name>
    <arm_group_label>BIOD-531 post-meal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 25 kg/m2

          -  Diabetes Mellitus using ≥ 150 units of insulin or insulin analog per day and/or ≥ 100
             units of insulin or insulin analog at a single dosing session for at least 1 month
             prior to screening

          -  HbA1c &lt; 10.0%

        Exclusion Criteria:

          -  History of bariatric surgery

          -  Corticosteroid therapy

          -  Significant cardiovascular or other major organ disease

          -  Females who are breast feeding or pregnant

          -  A sexually active person not using adequate contraceptive methods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurie Han-Conrad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institute for Clinical Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc. (PICR)</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <disposition_first_submitted>January 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>January 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 8, 2016</disposition_first_posted>
  <last_update_submitted>January 15, 2016</last_update_submitted>
  <last_update_submitted_qc>January 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

